ArticleJournal of fluorescence2026
First Fluorescence Method for Native Quantification of Pirtobrutinib Used for Treatment of Cancer in its Market Form and Biological Fluids; Application of Greenness.
Article in Journal of fluorescence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Spectrofluorometric and spectrophotometric assay of anticancer drug ensartinib using ion-pair complex formation reaction with eosin Y.Scientific reports · 2026Article
- Enhancing Blood Fingerprints with Multicolored Conjugated Polymers: A Fluorescent Strategy with Python-Based Quantitative Assessment.Journal of fluorescence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to determine the appropriate dosage of pirtobrutinib for treating mantle cell lymphoma that has returned or has not responded to prior treatment, a novel, straightforward, sensitive, and quick first spectrofluorometric approach has been devised. The technique uses 2% w/v sodium dodecyl sulfate (SDS) as an anionic surfactant to micellarly increase the drug’s natural fluorescence. Following excitation at 320 nm, the increased fluorescence intensity of pirtobrutinib was observed at 380 nm. An assay method for determining the researched drug was developed by analyzing the drug’s interaction with SDS and taking advantage of the increased fluorescence intensity. With a detection limit of 8.66 ng mL− 1 and a quantitation limit of 26.23 ng mL− 1, the relative fluorescence intensity-concentration graphs were rectilinear for the 30–1000 ng mL− 1 range. The results of the validation of the proposed analytical method in compliance with ICH standards were judged to be satisfactory. The suggested technique was effectively used for detection in tampered-with human plasma and pharmaceutical formulation. A number of assessment tools have lately been presented, as GAPI and AGREE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.